Generic drugmaker Aurobindo Pharma has received order under the Central Goods and Services Tax Act, 2017, asking it to pay GST, interest and a penalty of more than ₹155 crore. Additional ...

Generic drugmaker Aurobindo Pharma’s consolidated net profit declined 10% to ₹845.5 crore for the quarter ended December from ₹939.9 crore a year earlier amid lower formulations revenue in ...

Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third quarter ended December 31, 2024, by 10% to 846 crore from 940 crore ...

Aurobindo Pharma vice-chairman & managing director K Nithyananda Reddy said the company had reported its highest-ever quarterly revenue, driven by volume growth from its diverse and expanding ...

Addis Abeba- Gedion Timotheos, Ethiopia's Minister of Foreign Affairs, met with Türkiye's Deputy Foreign Minister Burhanettin Duran on Thursday, 06 February 2025, to discuss the upcoming ...

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the December quarter (Q3 FY25) to Rs 845.56 crore, down from Rs 939.97 crore ...

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales. However, the company achieved its highest-ever quarterly revenue at Rs 7,979 ...

Stocks from manufacturing and outsourcing hubs stand to benefit under the China Plus One strategy; Technical chart shows that shares of Amber, Aurobindo and others can rally up to 33% from here on.

Aurobindo Pharma posted a mixed financial performance for the December quarter, with strong revenue growth but a decline in net profit and margins. The company’s earnings failed to meet analysts’ ...

Aurobindo Pharma Ltd.'s third-quarter profit decreased 9.7% and missed analysts' estimates even as the company claimed to have clocked its "highest-ever" quarterly revenue. The Hyderabad-based bulk ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The stakes are clear. Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 billion by streamlining the resource- and time ...